{"id":5561,"date":"2015-07-01T07:34:00","date_gmt":"2015-07-01T07:34:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=5561"},"modified":"2021-07-12T07:54:04","modified_gmt":"2021-07-12T07:54:04","slug":"factors-associated-with-treatment-outcome-and-long-term-prognosis-of-patients-with-ulcerative-colitis-undergoing-selective-depletion-of-myeloid-lineage-leucocytes-a-prospective-multicenter-study","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/fr\/professional\/scientific-corner\/factors-associated-with-treatment-outcome-and-long-term-prognosis-of-patients-with-ulcerative-colitis-undergoing-selective-depletion-of-myeloid-lineage-leucocytes-a-prospective-multicenter-study\/","title":{"rendered":"Factors associated with treatment outcome, and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter study."},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>Selective myeloid leucocyte depletion was effective for remission induction and improving patients&rsquo; quality of life. Baseline demographics such as disease activity level, duration and corticosteroid dependency appear to predict response to GMA. Additionally, patients with a first UC episode who were drug naive responded well to GMA and achieved a favorable long-term disease course by avoiding pharmacologics from an early stage of their inflammatory bowel disease. These findings should help to end unnecessary use of medical resources by targeting GMA to patients who may respond well.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Yokoyama+Y&amp;cauthor_id=25804800\">Yoko Yokoyama<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25804800\/#affiliation-1\">1<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Watanabe+K&amp;cauthor_id=25804800\">Kenji Watanabe<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25804800\/#affiliation-2\">2<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Ito+H&amp;cauthor_id=25804800\">Hiroaki Ito<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25804800\/#affiliation-3\">3<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Nishishita+M&amp;cauthor_id=25804800\">Masakazu Nishishita<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25804800\/#affiliation-4\">4<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Sawada+K&amp;cauthor_id=25804800\">Koji Sawada<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25804800\/#affiliation-5\">5<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Okuyama+Y&amp;cauthor_id=25804800\">Yusuke Okuyama<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25804800\/#affiliation-6\">6<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Okazaki+K&amp;cauthor_id=25804800\">Kazuichi Okazaki<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25804800\/#affiliation-7\">7<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Fujii+H&amp;cauthor_id=25804800\">Hisao Fujii<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25804800\/#affiliation-8\">8<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Nakase+H&amp;cauthor_id=25804800\">Hiroshi Nakase<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25804800\/#affiliation-9\">9<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Masuda+T&amp;cauthor_id=25804800\">Tsutomu Masuda<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25804800\/#affiliation-10\">10<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Fukunaga+K&amp;cauthor_id=25804800\">Ken Fukunaga<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25804800\/#affiliation-11\">11<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Andoh+A&amp;cauthor_id=25804800\">Akira Andoh<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25804800\/#affiliation-12\">12<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Nakamura+S&amp;cauthor_id=25804800\">Shiro Nakamura<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25804800\/#affiliation-13\">13<\/a><\/sup> , <\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>Cytotherapy 2015 May;17(5):680-8.&nbsp;<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25804800\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/25804800\/<\/a><\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Selective myeloid leucocyte depletion was effective for remission induction and improving patients&rsquo; quality of life. Baseline demographics such as disease activity level, duration and corticosteroid dependency appear to predict response to GMA. Additionally, patients with a first UC episode who were drug naive responded well to GMA and achieved a favorable long-term disease course by [&hellip;]<\/p>\n","protected":false},"template":"","scientific_tags":[372,373,344,306],"class_list":["post-5561","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-long-term-prognosis","scientific_tags-platelets","scientific_tags-predictors","scientific_tags-ulcerative-colitis"],"acf":{"sc_authors":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Factors associated with treatment outcome, and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter study. - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/factors-associated-with-treatment-outcome-and-long-term-prognosis-of-patients-with-ulcerative-colitis-undergoing-selective-depletion-of-myeloid-lineage-leucocytes-a-prospective-multicenter-study\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Factors associated with treatment outcome, and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter study. - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Selective myeloid leucocyte depletion was effective for remission induction and improving patients&rsquo; quality of life. Baseline demographics such as disease activity level, duration and corticosteroid dependency appear to predict response to GMA. Additionally, patients with a first UC episode who were drug naive responded well to GMA and achieved a favorable long-term disease course by [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/factors-associated-with-treatment-outcome-and-long-term-prognosis-of-patients-with-ulcerative-colitis-undergoing-selective-depletion-of-myeloid-lineage-leucocytes-a-prospective-multicenter-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-12T07:54:04+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/factors-associated-with-treatment-outcome-and-long-term-prognosis-of-patients-with-ulcerative-colitis-undergoing-selective-depletion-of-myeloid-lineage-leucocytes-a-prospective-multicenter-study\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/factors-associated-with-treatment-outcome-and-long-term-prognosis-of-patients-with-ulcerative-colitis-undergoing-selective-depletion-of-myeloid-lineage-leucocytes-a-prospective-multicenter-study\/\",\"name\":\"Factors associated with treatment outcome, and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter study. - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2015-07-01T07:34:00+00:00\",\"dateModified\":\"2021-07-12T07:54:04+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/factors-associated-with-treatment-outcome-and-long-term-prognosis-of-patients-with-ulcerative-colitis-undergoing-selective-depletion-of-myeloid-lineage-leucocytes-a-prospective-multicenter-study\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Factors associated with treatment outcome, and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter study. - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/factors-associated-with-treatment-outcome-and-long-term-prognosis-of-patients-with-ulcerative-colitis-undergoing-selective-depletion-of-myeloid-lineage-leucocytes-a-prospective-multicenter-study\/","og_locale":"fr_FR","og_type":"article","og_title":"Factors associated with treatment outcome, and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter study. - Adacyte","og_description":"Selective myeloid leucocyte depletion was effective for remission induction and improving patients&rsquo; quality of life. Baseline demographics such as disease activity level, duration and corticosteroid dependency appear to predict response to GMA. Additionally, patients with a first UC episode who were drug naive responded well to GMA and achieved a favorable long-term disease course by [&hellip;]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/factors-associated-with-treatment-outcome-and-long-term-prognosis-of-patients-with-ulcerative-colitis-undergoing-selective-depletion-of-myeloid-lineage-leucocytes-a-prospective-multicenter-study\/","og_site_name":"Adacyte","article_modified_time":"2021-07-12T07:54:04+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/factors-associated-with-treatment-outcome-and-long-term-prognosis-of-patients-with-ulcerative-colitis-undergoing-selective-depletion-of-myeloid-lineage-leucocytes-a-prospective-multicenter-study\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/factors-associated-with-treatment-outcome-and-long-term-prognosis-of-patients-with-ulcerative-colitis-undergoing-selective-depletion-of-myeloid-lineage-leucocytes-a-prospective-multicenter-study\/","name":"Factors associated with treatment outcome, and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter study. - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2015-07-01T07:34:00+00:00","dateModified":"2021-07-12T07:54:04+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/factors-associated-with-treatment-outcome-and-long-term-prognosis-of-patients-with-ulcerative-colitis-undergoing-selective-depletion-of-myeloid-lineage-leucocytes-a-prospective-multicenter-study\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner\/5561","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/media?parent=5561"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific_tags?post=5561"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}